FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2733202912> ?p ?o ?g. }

• W2733202912 endingPage "295" @default.
• W2733202912 startingPage "289" @default.
• W2733202912 abstract "The search for small molecule inhibitors has gained prominence with the recognition of their inherent advantage for cancer therapy. Combretastatin is a naturally occurring small stilbenoid. By virtue of the ability to bind to tubulin combretastatin and its derivatives promote depolymerisation of microtubules as well as inhibit tubulin polymerisation. This suppresses cell proliferation signalling and induces apoptosis. Combretastatins activate mitotic checkpoints that lead to mitotic catastrophe and apoptosis. They subvert the signalling systems which stimulate invasion, activate EMT (epithelial mesenchyme transition) and promote tumour progression. Allied with the ability to suppress angiogenesis these compounds have been viewed as potential inhibitors of metastasis. The notion of merging RTK (receptor tyrosine kinase) inhibition with suppression of invasion and possible inhibition of EMT has contributed to the credibility of combretastatins as anti-cancer agents. Invaluable are their attributes of inhibiting tumour growth and induction of apoptosis and necrosis by reducing blood supply to the tumour. Aside from these biological effects, this commentary also discusses the issues of the targeting of combretastatins to the tumour vasculature and effective delivery of the drugs encapsulated in nanospheres. Notwithstanding the perceived benefits, one can see a compelling need to understand the effects of combretastatin on the actin cytoskeletal dynamics and the disruption of microtubule polymerisation, and whether it is more efficient a tumour inhibitor than the conventional drugs that target microtubule dynamics. Combinations of combretastatins with other vascular disrupting agents have been attempted. It is essential to establish the perceived inhibition of EMT beyond reasonable doubt. This might justify using the combretastatins with allosteric EMT and Akt inhibitors as additional choices for pre-clinical/clinical studies." @default.
• W2733202912 created "2017-07-14" @default.
• W2733202912 creator A5042571618 @default.
• W2733202912 date "2017-09-01" @default.
• W2733202912 modified "2023-09-27" @default.
• W2733202912 title "Suppression of angiogenesis and tumour progression by combretastatin and derivatives" @default.
• W2733202912 cites W1556732994 @default.
• W2733202912 cites W1689615548 @default.
• W2733202912 cites W1830531486 @default.
• W2733202912 cites W1968507507 @default.
• W2733202912 cites W1988263368 @default.
• W2733202912 cites W1993389739 @default.
• W2733202912 cites W1994297035 @default.
• W2733202912 cites W1995997339 @default.
• W2733202912 cites W2012358978 @default.
• W2733202912 cites W2019482378 @default.
• W2733202912 cites W2024304301 @default.
• W2733202912 cites W2031676888 @default.
• W2733202912 cites W2033567537 @default.
• W2733202912 cites W2034470452 @default.
• W2733202912 cites W2040294032 @default.
• W2733202912 cites W2041205020 @default.
• W2733202912 cites W2051455804 @default.
• W2733202912 cites W2059352954 @default.
• W2733202912 cites W2063935472 @default.
• W2733202912 cites W2064571598 @default.
• W2733202912 cites W2067278028 @default.
• W2733202912 cites W2072290539 @default.
• W2733202912 cites W2077192777 @default.
• W2733202912 cites W2084546943 @default.
• W2733202912 cites W2093855538 @default.
• W2733202912 cites W2095072642 @default.
• W2733202912 cites W2101546320 @default.
• W2733202912 cites W2104178524 @default.
• W2733202912 cites W2107697532 @default.
• W2733202912 cites W2111729275 @default.
• W2733202912 cites W2126087474 @default.
• W2733202912 cites W2127151407 @default.
• W2733202912 cites W2128773741 @default.
• W2733202912 cites W2132907046 @default.
• W2733202912 cites W2143346649 @default.
• W2733202912 cites W2148990197 @default.
• W2733202912 cites W2151089147 @default.
• W2733202912 cites W2151789399 @default.
• W2733202912 cites W2154747925 @default.
• W2733202912 cites W2164660906 @default.
• W2733202912 cites W2170523250 @default.
• W2733202912 cites W2171060779 @default.
• W2733202912 cites W2320830352 @default.
• W2733202912 cites W2335056549 @default.
• W2733202912 cites W2402558254 @default.
• W2733202912 cites W2422003189 @default.
• W2733202912 cites W2470289871 @default.
• W2733202912 cites W2471142276 @default.
• W2733202912 cites W2534223538 @default.
• W2733202912 cites W2563931996 @default.
• W2733202912 cites W2573197589 @default.
• W2733202912 cites W2593079932 @default.
• W2733202912 cites W575223411 @default.
• W2733202912 doi "https://doi.org/10.1016/j.canlet.2017.06.032" @default.
• W2733202912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28688972" @default.
• W2733202912 hasPublicationYear "2017" @default.
• W2733202912 type Work @default.
• W2733202912 sameAs 2733202912 @default.
• W2733202912 citedByCount "28" @default.
• W2733202912 countsByYear W27332029122017 @default.
• W2733202912 countsByYear W27332029122018 @default.
• W2733202912 countsByYear W27332029122019 @default.
• W2733202912 countsByYear W27332029122020 @default.
• W2733202912 countsByYear W27332029122021 @default.
• W2733202912 countsByYear W27332029122022 @default.
• W2733202912 countsByYear W27332029122023 @default.
• W2733202912 crossrefType "journal-article" @default.
• W2733202912 hasAuthorship W2733202912A5042571618 @default.
• W2733202912 hasConcept C121608353 @default.
• W2733202912 hasConcept C186000732 @default.
• W2733202912 hasConcept C190283241 @default.
• W2733202912 hasConcept C20418707 @default.
• W2733202912 hasConcept C2778275628 @default.
• W2733202912 hasConcept C2780394083 @default.
• W2733202912 hasConcept C31573885 @default.
• W2733202912 hasConcept C502942594 @default.
• W2733202912 hasConcept C54355233 @default.
• W2733202912 hasConcept C55493867 @default.
• W2733202912 hasConcept C84425145 @default.
• W2733202912 hasConcept C86803240 @default.
• W2733202912 hasConcept C93304396 @default.
• W2733202912 hasConcept C95444343 @default.
• W2733202912 hasConcept C96232424 @default.
• W2733202912 hasConceptScore W2733202912C121608353 @default.
• W2733202912 hasConceptScore W2733202912C186000732 @default.
• W2733202912 hasConceptScore W2733202912C190283241 @default.
• W2733202912 hasConceptScore W2733202912C20418707 @default.
• W2733202912 hasConceptScore W2733202912C2778275628 @default.
• W2733202912 hasConceptScore W2733202912C2780394083 @default.
• W2733202912 hasConceptScore W2733202912C31573885 @default.
• W2733202912 hasConceptScore W2733202912C502942594 @default.
• W2733202912 hasConceptScore W2733202912C54355233 @default.

• next